Published in Leuk Res on October 11, 2011
Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett (2012) 1.64
C/EBPα in normal and malignant myelopoiesis. Int J Hematol (2015) 1.06
Klf5 controls bone marrow homing of stem cells and progenitors through Rab5-mediated β1/β2-integrin trafficking. Nat Commun (2013) 0.91
Granulopoiesis requires increased C/EBPα compared to monopoiesis, correlated with elevated Cebpa in immature G-CSF receptor versus M-CSF receptor expressing cells. PLoS One (2014) 0.89
CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation. Sci Rep (2014) 0.76
Eicosapentaenoic acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. PLoS One (2014) 0.76
DNMT1-maintained hypermethylation of Krüppel-like factor 5 involves in the progression of clear cell renal cell carcinoma. Cell Death Dis (2017) 0.75
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet (2011) 3.41
Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res (2003) 2.73
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood (2011) 2.66
Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling. J Biol Chem (2002) 1.97
Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant (2013) 1.80
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res (2008) 1.62
Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res (2005) 1.40
Long-term imatinib therapy promotes bone formation in CML patients. Blood (2007) 1.30
Genome-wide identification of human FOXP3 target genes in natural regulatory T cells. J Immunol (2010) 1.28
An optimized algorithm for detecting and annotating regional differential methylation. BMC Bioinformatics (2013) 1.27
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood (2005) 1.21
BMP4: its role in development of the hematopoietic system and potential as a hematopoietic growth factor. Stem Cells (2004) 1.18
The nucleotide-binding site of human sphingosine kinase 1. J Biol Chem (2002) 1.14
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol (2007) 1.10
Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia (2011) 1.02
Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. J Bone Miner Res (2009) 1.00
Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood (2009) 0.97
Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common beta-subunit. Blood (2010) 0.97
Homing defect of cultured human hematopoietic cells in the NOD/SCID mouse is mediated by Fas/CD95. Exp Hematol (2003) 0.97
Dynamic evolution of clonal epialleles revealed by methclone. Genome Biol (2014) 0.97
Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors. Proc Natl Acad Sci U S A (2012) 0.96
A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leuk Lymphoma (2014) 0.96
The GM-CSF receptor family: mechanism of activation and implications for disease. Growth Factors (2012) 0.93
Development of CD4+CD25+FoxP3+ regulatory T cells from cord blood hematopoietic progenitor cells. J Leukoc Biol (2008) 0.92
Genetic regulators of myelopoiesis and leukemic signaling identified by gene profiling and linear modeling. J Leukoc Biol (2006) 0.92
Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma (2006) 0.89
HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia. Oncotarget (2013) 0.89
Functional cross-talk between cytokine receptors revealed by activating mutations in the extracellular domain of the beta-subunit of the GM-CSF receptor. J Leukoc Biol (2002) 0.89
Signalling by the βc family of cytokines. Cytokine Growth Factor Rev (2013) 0.88
Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient. Br J Haematol (2011) 0.87
Comparison of twin and autologous transplants for multiple myeloma. Biol Blood Marrow Transplant (2008) 0.87
Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myeloma. Clin Cancer Res (2006) 0.86
Cotransplantation of placental mesenchymal stromal cells enhances single and double cord blood engraftment in nonobese diabetic/severe combined immune deficient mice. Stem Cells (2009) 0.86
The preferential occurrence of FLT3-TKD mutations in inv(16) AML and impact on survival outcome: a combined analysis of 1053 core-binding factor AML patients. Br J Haematol (2012) 0.84
Bone morphogenetic protein 4 contributes to the maintenance of primitive cord blood hematopoietic progenitors in an ex vivo stroma-noncontact co-culture system. Stem Cells Dev (2006) 0.83
The vent-like homeobox gene VENTX promotes human myeloid differentiation and is highly expressed in acute myeloid leukemia. Proc Natl Acad Sci U S A (2010) 0.83
Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant (2008) 0.83
The double life of KLF5: Opposing roles in regulation of gene-expression, cellular function, and transformation. IUBMB Life (2013) 0.82
Constitutive mutants of the GM-CSF receptor reveal multiple pathways leading to myeloid cell survival, proliferation, and granulocyte-macrophage differentiation. Blood (2003) 0.82
One-step Melt Synthesis of Water Soluble, Photoluminescent, Surface-Oxidized Silicon Nanoparticles for Cellular Imaging Applications. Chem Mater (2011) 0.81
p53-Dependent transcriptional responses to interleukin-3 signaling. PLoS One (2012) 0.81
Potential therapeutic applications of mesenchymal stromal cells. Pathology (2011) 0.80
Hematopoietic growth factor mimetics: from concept to clinic. Cytokine Growth Factor Rev (2009) 0.80
Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling. Cancer Res (2013) 0.80
RUNX1 mutations are rare in chronic phase polycythaemia vera. Br J Haematol (2011) 0.79
The GM-CSF receptor utilizes β-catenin and Tcf4 to specify macrophage lineage differentiation. Differentiation (2011) 0.79
Methylation of KLF5 contributes to reduced expression in acute myeloid leukaemia and is associated with poor overall survival. Br J Haematol (2013) 0.79
Potential for clinical ex vivo expansion of cord blood haemopoietic stem cells using non-haemopoietic factor supplements. Curr Stem Cell Res Ther (2007) 0.77
Post-transplant plasmablastic lymphoma of the skin. Australas J Dermatol (2012) 0.77
A phase I study of the GM-CSF antagonist E21R. Cancer Chemother Pharmacol (2002) 0.77
Cooperation of cytokine signaling with chimeric transcription factors in leukemogenesis: PML-retinoic acid receptor alpha blocks growth factor-mediated differentiation. Mol Cell Biol (2003) 0.77
A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia. Br J Haematol (2014) 0.76
Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia. Expert Opin Pharmacother (2015) 0.76
Outcomes of lymphoma in South Australia, 1977-2007. Med J Aust (2012) 0.75
New sequence-tagged site molecular markers for identification of sex in Distichlis spicata. Mol Ecol Resour (2009) 0.75
Genome-wide gene expression profiling identifies overlap with malignant adrenocortical tumours and novel mechanisms of inefficient steroidogenesis in familial ACTH-independent macronodular adrenal hyperplasia. Endocr Relat Cancer (2012) 0.75
Cellular origin and lineage specificity of the JAK2(V617F) allele in polycythemia vera. Blood (2007) 0.75
Erratum to "Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study" [Biol Blood Marrow Transplant 2016;22:1410-1415]. Biol Blood Marrow Transplant (2016) 0.75
Mobilisation strategies for normal and malignant cells. Pathology (2011) 0.75
Unraveling the "known unknowns": lessons and reflections from the new directions in leukemia research 2012 conference. Cancer Res (2012) 0.75
An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors. Methods Mol Med (2005) 0.75